[The hinge region of therapeutic antibodies: major importance of a short sequence]
- PMID: 31903923
- DOI: 10.1051/medsci/2019218
[The hinge region of therapeutic antibodies: major importance of a short sequence]
Abstract
The hinge region is a short sequence of the heavy chains (H) of antibodies linking the Fab (Fragment antigen binding) region to the Fc (Fragment crystallisable) region. The functional properties of the four IgG subclasses partly result from the sequence differences of their hinge regions as some amino acids of the lower hinge region are located within or in the close vicinity of the C1q and FcγR binding sites on the IgG H chains. In addition, the hinge is susceptible to proteolytic cleavage by many proteases present in tumor and/or inflammatory microenvironment capable of affecting functional responses. Thus, an optimal format of the hinge region remains a major challenge for the development of new therapeutic antibodies.
Title: La région charnière des anticorps thérapeutiques - L’importance capitale d’une courte séquence.
Abstract: La région charnière est une courte séquence des chaînes lourdes (H) d’anticorps liant le Fab (fragment antigen binding) au Fc (fragment crystallisable). Les propriétés fonctionnelles des quatre sous-classes d’immunoglobulines d’isotype G (IgG) résultent en partie des différences de séquence de leurs régions charnières. En effet, certains acides aminés de la partie C-terminale de ces régions charnières (« partie basse ») sont situés au sein ou à proximité des sites de liaison de la molécule C1q de la voie classique du complément et des récepteurs pour la région Fc des IgG (RFcγ) sur les chaînes H d’IgG. Les régions charnières sont également sensibles au clivage protéolytique par de nombreuses protéases du microenvironnement tumoral et/ou inflammatoire pouvant altérer les réponses fonctionnelles. Le format optimal de la charnière reste donc un défi majeur pour le développement de nouveaux anticorps thérapeutiques.
© 2019 médecine/sciences – Inserm.
Similar articles
-
The Proteolytic Cleavage of Therapeutic Monoclonal Antibody Hinge Region: More Than a Matter of Subclass.Front Immunol. 2020 Feb 11;11:168. doi: 10.3389/fimmu.2020.00168. eCollection 2020. Front Immunol. 2020. PMID: 32117299 Free PMC article.
-
Structural determinants of unique properties of human IgG4-Fc.J Mol Biol. 2014 Feb 6;426(3):630-44. doi: 10.1016/j.jmb.2013.10.039. Epub 2013 Nov 6. J Mol Biol. 2014. PMID: 24211234 Free PMC article.
-
Identification of cysteinylation of a free cysteine in the Fab region of a recombinant monoclonal IgG1 antibody using Lys-C limited proteolysis coupled with LC/MS analysis.Anal Biochem. 2006 Aug 15;355(2):165-74. doi: 10.1016/j.ab.2006.05.037. Epub 2006 Jun 15. Anal Biochem. 2006. PMID: 16828048
-
Cleavage of IgGs by proteases associated with invasive diseases: an evasion tactic against host immunity?MAbs. 2010 May-Jun;2(3):212-20. doi: 10.4161/mabs.2.3.11780. Epub 2010 May 23. MAbs. 2010. PMID: 20400859 Free PMC article. Review.
-
Structural analysis of Fc/FcγR complexes: a blueprint for antibody design.Immunol Rev. 2015 Nov;268(1):201-21. doi: 10.1111/imr.12365. Immunol Rev. 2015. PMID: 26497522 Review.
Cited by
-
Introduction of Carbonyl Groups into Antibodies.Molecules. 2023 Dec 1;28(23):7890. doi: 10.3390/molecules28237890. Molecules. 2023. PMID: 38067618 Free PMC article. Review.
References
-
- Burton DR , Immunoglobulin G: functional sites. Mol Immunol. 1985;22:161–206.
-
- Ugurlar D, Howes SC, de Kreuk BJ, et al., Structures of C1-IgG1 provide insights into how danger pattern recognition activates complement. Science. 2018;359:794–7.
-
- Strasser J, De Jong RN, Beurskens FJ, et al., Unraveling the macromolecular pathways of IgG oligomerization and complement activation on antigenic surfaces. Nano Lett. 2019;19:4787–96.
-
- Bindon CI , Human monoclonal IgG isotypes differ in complement activating function at the level of C4 as well as C1q. J Exp Med. 1988;168:127–42.
-
- Morgan A, Jones ND, Nesbitt AM, et al., The N-terminal end of the CH2 domain of chimeric human IgG1 anti-HLA-DR is necessary for C1q, Fc gamma RI and Fc gamma RIII binding. Immunology. 1995;86:319–24.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources